What development phase is INTERFERON GAMMA-1A in?

INTERFERON GAMMA-1A is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

INTERFERON GAMMA-1A

FDA-approved active Recombinant protein Quality 0/100

Interferon Gamma-1A is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	INTERFERON GAMMA-1A
Modality	Recombinant protein
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

INTERFERON GAMMA-1A CI brief — competitive landscape report
INTERFERON GAMMA-1A updates RSS · CI watch RSS